Background: 44 With spot urine collected from a large control sample of preschool children (aged 3-7 years), 45 reference range of spot urine copper excretion indexes and their biological variation were defined.
4
Conclusions: 65 Based on the data, a new WD screening time window targeting preschool children is proposed. 66 Application of a bivariate screening strategy using spot urine copper concentration and urine 67 osmolality may be useful in a population screening program for preschool children. Wilson's disease (WD) is a common inherited disease of copper metabolism caused by mutations in 72 ATP7B gene (OMIM: 277900). The disease incidence in the range of one in thousands is one of the 73 highly prevalent inherited metabolic diseases (IMD), particularly in Asian populations (1, 2) . In the 74 past, WD were typically diagnosed after symptoms onset due to cumulative damage to the liver 75 (hepatic presentation) or CNS (neurologic presentation) after a prolonged period of copper 76 accumulation and diagnosis has been made with a clinicopathologic scoring system (3, 4) . 77 Nowadays, with the advance in molecular diagnosis, a clear-cut definitive diagnosis for both 78 affected and heterozygotes can be readily made. As early diagnosis and treatment are the key 79 determinants of prognosis, there have been attempts of screening using various biomarkers (5) . 80 Here, we studied the reference interval of spot urine copper excretion in healthy preschool children 81 (age 3 to 7) and examined the feasibility of its application as a screening biomarker for WD.
83
With the help of mutation analysis for diagnosis the natural history of WD is changed. More and 84 more young presymptomatic WD patients have been diagnosed before adolescence and treatment 85 can be started early with the potential of preventing significant organ damage and hopefully 86 attaining uneventful life expectancy similar to healthy individuals (6-9). Early and safe treatment of 87 these presymptomatic WD with oral zinc therapy is effective in reducing dietary copper absorption 88 and thus body copper load (6-9). The benefit of early treatment stems from the ability to make early diagnosis in WD patients 91 particularly before 10-years-of-age. This represents a wide (a decade long) presymptomatic window 92 6 period for making the early diagnosis before significant tissue damage occurs. Nature history of 93 WD also supports this notion. First, neurological diseases have a typical onset after adolescence (2).
94
Second, liver toxicity due to cumulative copper toxicity also commonly occurs after 10-years-of-age 95 (8). Currently, presymptomatic patients were largely picked up by family screening after index 96 cases had been diagnosed. While others were solely relied on clinical vigilance of the paediatricians 97 when managing patients with unexplained symptoms and laboratory results, such as persistent 98 elevation of liver enzymes (10). However, no biomarker suitable for large-scale case screening is 99 available though some attempts had been reported (5).
101
While 24-hour urine copper is the gold standard in the assessment of urine copper excretion in WD, 102 its collection in children is difficult and it is not practical in large scale screening. Our previous 103 attempts to develop a cut-off value of spot urine magnesium in the assessment of body magnesium 104 status motivated us to develop a similar index for evaluation of copper excretion (11). These spot 105 urine excretion indexes may have a role in triage of patients with suspected Wilson's disease or 106 even population screening of pre-symptomatic Wilson's disease among preschool children.
108
To make such a spot urine index useful, we must first evaluate the reference intervals (RI) which are 7 In this article, we first examined the reference intervals spot urine copper excretion indexes among 115 153 preschool children. Then, data of urine excretion from prevalent paediatric WD patients were 116 compared to these reference intervals to show the potential test utility of these biomarkers. The 117 results are promising with good sensitivity, suggesting that WD screening by spot urine in preschool 118 children is feasible. Six WD patients who were diagnosed before the age of 11 and had been followed up in outpatient 144 clinic were invited to participate. Their diagnosis had been confirmed by mutation analysis of the 145 ATP7B gene (10). 2-3 spot urine samples of the same day in addition to a next day standard 24-hour 146 urine sample for copper excretion monitoring were collected. Patients' data were subdivided (Table 1) 165 Among the 153 preschool children older than 3 years, the spot urine copper concentration had a 166 median 0.19 µmol/L with inter-quartile values from 0.09 to 0.28 µmol/L. Only 4 children (3%) had 167 a urine copper concentration exceeding 0.5 µmol/L. These values were 0.51, 0.52, 0.54 and 0.55 168 µmol/L. Although there was a mild age effect on spot urine copper concentration (increase by 0.026 169 µmol/L per year, p=0.02), the effect of age was corrected after normalization by creatinine or 170 osmolality supporting the use of these ratios or bivariate interpretation (Supplemental Figure 1 ).
Spot urine copper excretion indexes in preschool children
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The two normalised indexes were investigated, namely copper to creatinine ratio and copper to 173 osmolality ratio and their mean values were 0.05 µmol/mmol and 0.000353 µmol/mOsm, On the other hand, spot urine copper excretion was much higher in the patient groups irrespective of 179 duration of treatment. Among 37 spot urine samples (with creatinine results) collected from all 6 180 WD patients, the median copper concentration was 1.10 µmol/L with inter-quartile values from 0.60 181 to 1.30 µmol/L. There were 6 samples (19%) with spot urine copper below 0.5 µmol/L ( Figure 1A ).
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Most of them (4 out of 6) were collected from patients whom received more than one year of 183 treatment so these urine samples were categorised into the subgroups in subsequent analysis. 186 It is a common practice to normalised spot urine excretion by creatinine. Indeed, spot urine copper 187 concentration showed a strong correlation with spot urine creatinine concentration among controls 188 (Pearson r=0.62, p≤2.2x10 -16 , Figure 2a ). The predicted range of 95% distribution of individual data For patients after long term treatment, spot urine copper excretion tends to reduce and approach 198 towards that in the control (red triangle symbols in Figure 2b ). Three WD patient (after treatment) 199 samples fell into the prediction range of control (Figure 2b) . The 2 regression lines (one for control 200 and one for WD patients) represent urine copper to creatinine ratios and difference in two slopes 201 could clearly differentiate between patients and control. The median urine copper to creatinine ratio 202 were 0.23 (WD patients at diagnosis) and 0.17 (WD patients after treatment), which were almost 6 203 folds and 4 folds higher to that of the controls, 0.04 ( Figure 1B) . Therefore, 0.1 may be a reasonable 204 cut-off value for urine copper to creatinine ratio to demarcate WD patients from controls which was 205 marked in the subsequent ROC plot (Figure 4 ). In addition, the spot urine may also be useful in 206 monitoring patients' responses after treatment. 209 Likewise, spot urine copper concentration showed a highly significant correlation with spot urine 210 osmolality among controls (Pearson r=0.6, p=<2.2x10 -16 , Figure 3A ). In the scatter plot Figure 3A , 211 there is a good demarcation between patients and controls. As only 3 data points were available 212 from WD patient at diagnosis, all WD samples (N=22) were analysed together. There was only one 213 WD sample that was located in the predicted range of control data. This samples were one of the 214 more dilute urine samples collected from a patient at osmolality of 206 mOsmol/kg. When the 215 distribution of the copper to osmolality ratio ( Figure 3B) were analysed, the control group had a 216 median of 0.00032 and a quartile range from 0.00024 to 0.00043. Meanwhile, the median in WD 217 patients were 0.0012 with a quartile range from 0.001 to 0.0016. A cut-off value of 0.00085 could 218 be used to differentiate WD from controls. In fact, both copper concentration and the copper to creatinine ratio can easily differentiate them.
Spot urine copper correlated with urine creatinine in control preschool children
Spot urine to osmolality ratio is the best biomarker
227
ROC analysis of all indexes had area-under-curve (AUC) values of greater than 0.95 and over 90% 228 sensitivity in identification of WD from health preschool children control (Figure 4) . The best index was spot urine copper to osmolality ratio, which had the highest AUC of 0.98. Both 231 sensitivity and specificity were better than 0.95 at cut-off value of 0.00085. Therefore, it is likely 232 that such bivariate classifier will be used in future implementations.
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For example, there was an overlap if the urine sample was dilute urine (at the low end of creatinine 235 concentration). Therefore, low spot urine osmolality or creatinine concentration could be used as an 236 additional filter to call for repeat. For example, spot urine osmolality lower than 500 or creatinine 237 concentration lower than 1.5 mmol/L will be used as criteria to call for repeat samples. 254 Timing of screening for WD is very important. Many previous attempts with limited success had 255 targeted to screen WD at newborn (5). However, such approach is restricted by the limited exposure 256 to copper of the foetus before birth resulting a small body copper load at birth. Here, we propose a 257 novel screening strategy to make use of the fairly long presymptomatic phase of WD to screen at 258 preschool age or before 10 years-of-age. Such flexibility also allows better integration into the local Our long-term interest in nutritional research and biomarker studies provided us an insight into the 263 application of spot urine as biomarkers (11, 16) . In the past, we pioneered the use of spot urine 264 magnesium as a biomarker for assessment of body status of magnesium (11) and it had been used in 265 both clinical and research settings (17, 18) . There were other groups which carried out pilot studies 266 in the use of spot urine in assessment of body status or dietary intake of sodium (19-21), 267 magnesium and other trace elements (22, 23) . Spot urine collection is a common practice in the Furthermore, the evaluation of these variations in the paediatric age group is also lacking. Our study 276 fills in this knowledge gap and supports the potential of use of spot urine copper index (in particular 277 spot urine to osmolality ratio) in the screening of WD among preschool children.
In search of a suitable biomarker for large scale screening of WD
279
With the ultimate goal of identifying a screening biomarker for WD of high sensitivity and 280 specificity, both spot urine copper to creatinine and urine to osmolality ratios showed a huge 281 potential in this study. While all spot urine indexes were informative, urine to osmolality may have 282 an edge over other 2 parameters. An example strategy using bivariate screening approach is shown 283 in Figure 5 . Spot urine biomarkers have several obvious advantages over other blood markers.
284
Firstly, it is non-invasive and large scale screening application can be easily implemented and 285 16 compliance is not a problem. Secondly, repeat sample or a multiple sample collection protocol 286 could be arranged. Advances in molecular genetics nowadays enable the definite diagnosis of WD 287 to be made robustly (26) . The presence of locally prevalent mutations also enhances the diagnostic 288 efficiency. Presymptomatic WD patients picked up by spot urine screening can be followed by a 289 molecular test to make the definite diagnosis.
291
While there is a long-held myth that urine copper excretion is highly variable (3), we showed that it 292 was not the case in the control preschool children. In fact, urine excretion of magnesium and copper 293 had the least biological variation among all trace metals, in terms of intra-individual variation (27) . 294 The data suggests that spot urine concentration of copper correlates with the average daily 295 concentration in a 24-hour urine. This property of low biological variation provides the explanation 296 that spot urine excretion is a reliable biomarker for selected elements like magnesium and copper. In 297 the past, many confounding factors of urine copper excretion had been described, e.g. kidney 298 disease, acute liver failure, hepatitis which were commonly listed as differential causes of elevated 299 urine copper excretion. However, many of them are only found in the hospital setting but do not 300 apply if urine is collected from presymptomatic (healthy) subjects. Therefore, they do not come into 301 the picture in the setting of screening for presysmptomatic WD among healthy children.
303
There is a normal range of excretion in relation to creatinine or osmolality in the spot urine sample.
304
These parameters differentiate early WD patients from controls fairly robustly with AUC greater 305 than 0.95. On the other hand, such differentiation may be blurred in symptomatic WD patients who 306 also had proteinuria or patients with other causes of proteinuria, as spot urine copper assessment is 307 no longer valid for assessment of body copper status. Therefore, it is advisable to perform a 308 17 proteinuria assessment together with spot urine copper as a screening package or subsequent follow-309 up test. Any samples with significant proteinuria will invalid the screening.
311
Limitation of the study 312 This is the first attempt to use a bivariate analysis of spot urine for screening of WD in preschool 313 children. We had data from only 6 WD patients in this age range. Although our results are 314 encouraging, more data from childhood WD patients are required to fully understand the biological 315 variation of spot urine copper excretion in early WD. Future multi-centre studies will be required to 316 gather data from more patients. Figure 3B shows the distribution of urine copper to osmolality ratios (µmol/mOsm) among three 426 groups of subjects. All WD patients at diagnosis had ratio above 0.00085. The value of control 427 group was significantly lower than the two patients' groups (p values <1e-12). osmolality. Samples of low osmolality will be taken as non-diagnostic and subjects will be called to 438 repeat. Subjects with samples inside the screen-positive area will be followed up with additional 439 definitive tests.
